HLX43
Drug timelines are a Plus or Pro feature.
17 regulatory and trial events tracked for HLX43, covering 2025-03-10 to 2026-04-22. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors [Phase 2]